Compare Consolidated Edison, Inc. (ED) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs 22nd Century Group Inc — how do they compare? Consolidated Edison, Inc. trades at $105.97 (market cap $39.20B), while 22nd Century Group Inc trades at $0.84 (market cap $621.67K). The key difference: Consolidated Edison, Inc. is far larger — about 63056× 22nd Century Group Inc's market cap, and Consolidated Edison, Inc. pays a 3.31% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and 22nd Century Group Inc for 32 Days on average.
| ED | XXII | |
|---|---|---|
Market Cap | $39.20B | $621.67K |
Volume | 2,142,900 | 45,625 |
Sector | Utilities | Consumer Staples |
52-Week High | $115.46 | $483.00 |
52-Week Low | $95.37 | $0.80 |
Typical Hold Time | 75 Days | 32 Days |
Enterprise Value | $66.05B | -$3.69M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $105.94, up 1.23% today, near the consensus price target of $106.33. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages, while fundamentals reflect steady utility performance with 2025 revenue of $16.92B and net income of $2.02B. Recent news highlights its $24.8B economic impact in New York and upcoming investor webcast, reinforcing its stable dividend aristocrat status.
ED offers a defensive investment with a reliable dividend and moderate growth, but faces risks from high debt levels and interest expenses. Analyst sentiment is cautious with 62.96% hold ratings, suggesting limited near-term upside despite solid cash flow generation. The stock's appeal lies in its income stability amid economic uncertainty, though execution on capital expenditures remains key to sustaining growth.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
